|
2025 Journal Article The effect of oral colchicine and vitamin K1 on bone metabolism in patients with diabetes mellitus: A post-hoc analysis of a 2 × 2 factorial randomized controlled trial with 18F-sodium fluoride positron emission tomographyBellinge, Jamie W., Sim, Marc, Francis, Roslyn J., Lee, Sing Ching, Chan, Dick C., Girgis, Christian M., Watts, Gerald F., Lewis, Joshua R. and Schultz, Carl J. (2025). The effect of oral colchicine and vitamin K1 on bone metabolism in patients with diabetes mellitus: A post-hoc analysis of a 2 × 2 factorial randomized controlled trial with 18F-sodium fluoride positron emission tomography. Bone, 196 117492, 117492. doi: 10.1016/j.bone.2025.117492 |
|
2025 Journal Article Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialKwan, Edmond M., Ng, Sarah W. S., Tolmeijer, Sofie H., Emmett, Louise, Sandhu, Shahneen, Buteau, James P., Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze-Ting, Scott, Andrew M., Martin, Andrew J., Stockler, Martin R., Donnellan, Grainne, Annala, Matti, Herberts, Cameron, Davis, Ian D., Hofman, Michael S., Azad, Arun A., Wyatt, Alexander W., Akhurst, Tim, Alipour, Ramin, Bailey, Dale L., Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Chua, Wei, Crumbaker, Megan ... Zhang, Alison Y. (2025). Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nature Medicine, 1-15. doi: 10.1038/s41591-025-03704-9 |
|
2025 Journal Article Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA StudyChen, David C., Buteau, James P., Emmett, Louise, Alipour, Ramin, de Galiza Barbosa, Felipe, Roberts, Matthew J., McVey, Aoife, O’Brien, Jonathan, Levy, Sidney, Francis, Roslyn J., Lawrentschuk, Nathan, Murphy, Declan G. and Hofman, Michael S. (2025). Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study. Journal of Nuclear Medicine, 66 (5), 713-718. doi: 10.2967/jnumed.124.268901 |
|
2025 Journal Article Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST studyFielding, David, Sidhu, Calvin, Alkhater, Mahmoud, Alawami, Moayed, Kops, Stephan E P, van der Heijden, Erik H F M, Bashirzadeh, Farzad, Windsor, Morgan, Nixon, Elizabeth, Son, Jung Hwa, Ananda Setty, Niranjan, Pattison, David A, Fong, William, Bhatt, Manoj, Dhiantravan, Nattakorn, Ramsay, Stuart, Boots, Robert, Putt, Michael, Pratt, Gary, Bettington, Catherine, Francis, Roslyn, Thomas, Paul, Steinke, Karin and Thomas, Rajesh (2025). Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST study. BMJ Open Respiratory Research, 12 (1) e002553, e002553. doi: 10.1136/bmjresp-2024-002553 |
|
2025 Journal Article An External, Independent Validation of an<i>O</i>-(2-[<sup>18</sup>F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with GlioblastomaBarry, Nathaniel, Kendrick, Jake, Rowshanfarzad, Pejman, Hassan, Ghulam Mubashar, Francis, Roslyn J., Bucknell, Nicholas, Koh, Eng-Siew, Scott, Andrew M., Ebert, Martin A., Gutsche, Robin, Ciantar, Keith George, Galldiks, Norbert, Langen, Karl-Josef and Lohmann, Philipp (2025). An External, Independent Validation of anO-(2-[18F]Fluoroethyl)-l-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma. Journal of Nuclear Medicine, 66 (6), jnumed.124.268925-953. doi: 10.2967/jnumed.124.268925 |
|
2025 Journal Article Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M, Sandhu, Shahneen, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Kumar, Aravind S Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Bills, Madison (2025). Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (3), 291-299. doi: 10.1016/s1470-2045(25)00009-9 |
|
2025 Journal Article Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [68Ga]Ga-PSMA-11 PET/CTMolin, Kaylee, Barry, Nathaniel, Gill, Suki, Hassan, Ghulam Mubashar, Francis, Roslyn J., Ong, Jeremy S. L., Ebert, Martin A. and Kendrick, Jake (2025). Evaluating the prognostic value of radiomics and clinical features in metastatic prostate cancer using [68Ga]Ga-PSMA-11 PET/CT. Physical and Engineering Sciences in Medicine, 48 (1), 329-341. doi: 10.1007/s13246-024-01516-8 |
|
2025 Journal Article Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccineThunold, Solfrid, Hernes, Eivor, Farooqi, Saima, Öjlert, Åsa Kristina, Francis, Roslyn J., Nowak, Anna K., Szejniuk, Weronika Maria, Nielsen, Søren Steen, Cedres, Susana, Perdigo, Marc Simo, Sørensen, Jens Benn, Meltzer, Carin, Mikalsen, Lars Tore Gyland, Helland, Åslaug, Malinen, Eirik and Haakensen, Vilde Drageset (2025). Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine. European Journal of Nuclear Medicine and Molecular Imaging, 52 (2), 693-707. doi: 10.1007/s00259-024-06853-0 |
|
2025 Journal Article Fluorodeoxyglucose Positron Emission Tomography Detects Persistent Arterial Inflammation After Symptomatic COVID-19Espedal, Heidi, Verma, Shipra, Roy, Ambuj, Lan, Nick S.R., Mohd, Sheeraz, Bartlett, Benjamin, Ali, Kamar, Ward, Natalie C., Ebert, Martin A., Chan, Dick C., Watts, Gerald F., Dwivedi, Girish and Francis, Roslyn J. (2025). Fluorodeoxyglucose Positron Emission Tomography Detects Persistent Arterial Inflammation After Symptomatic COVID-19. Heart Lung and Circulation. doi: 10.1016/j.hlc.2025.03.005 |
|
2024 Journal Article Assessing the heterogeneity of response of [68Ga] Ga-PSMA-11 PET/CT lesions in patients with biochemical recurrence of prostate cancerDell'Oro, Mikaela, Huff, Daniel T., Lokre, Ojaswita, Kendrick, Jake, Munian Govindan, Rajkumar, Ong, Jeremy S. L., Ebert, Martin A., Perk, Timothy G. and Francis, Roslyn J. (2024). Assessing the heterogeneity of response of [68Ga] Ga-PSMA-11 PET/CT lesions in patients with biochemical recurrence of prostate cancer. Clinical Genitourinary Cancer, 22 (5) 102155, 102155. doi: 10.1016/j.clgc.2024.102155 |
|
2024 Journal Article Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 studyAzad, Arun A, Bressel, Mathias, Tan, Hsiang, Voskoboynik, Mark, Suder, Aneta, Weickhardt, Andrew J, Guminski, Alexander, Francis, Roslyn J, Saghebi, Javad, Dhiantravan, Nattakorn, Joshua, Anthony M, Emmett, Louise, Horvath, Lisa, Murphy, Declan G, Hsiao, Edward, Balakrishnar, Bavanthi, Lin, Peter, Redfern, Andrew, Macdonald, William, Ng, Siobhan, Lee, Sze-Ting, Pattison, David A, Nadebaum, David, Kirkwood, Ian D, Hofman, Michael S, Akhurst, T, Alipour, R, Au, L, Banks, P ... Ratnayake, L (2024). Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. The Lancet Oncology, 25 (10), 1267-1276. doi: 10.1016/s1470-2045(24)00440-6 |
|
2024 Journal Article Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CTParry, R., Wright, K., Bellinge, J. W., Ebert, M. A., Rowshanfarzad, P., Francis, R. J. and Schultz, C. J. (2024). Training and assessing convolutional neural network performance in automatic vascular segmentation using Ga-68 DOTATATE PET/CT. International Journal of Cardiovascular Imaging, 40 (9), 1847-1861. doi: 10.1007/s10554-024-03171-2 |
|
2024 Journal Article The Australian Traumatic Brain Injury Initiative: systematic review of clinical factors associated with outcomes in people with moderate-severe traumatic brain injuryMcKimmie, Ancelin, Keeves, Jemma, Gadowski, Adelle, Bagg, Matthew K., Antonic-Baker, Ana, Hicks, Amelia J., Hill, Regina, Clarke, Nyssa, Holland, Andrew, Veitch, Bill, Fatovich, Daniel, Reeder, Sandy, Romero, Lorena, Ponsford, Jennie L., Lannin, Natasha A., O’Brien, Terence J., Cooper, D. Jamie, Rushworth, Nick, Fitzgerald, Melinda, Gabbe, Belinda J., Cameron, Peter A., Alexander, Tara, Anderson, Vicki, Armstrong, Elizabeth, Babl, Franz E., Balogh, Zsolt J., Barlow, Karen M. (AUS-TBI Investigators member), Bellapart, Judith, Bidargaddi, Niranjan ... Zeeman, Heidi (2024). The Australian Traumatic Brain Injury Initiative: systematic review of clinical factors associated with outcomes in people with moderate-severe traumatic brain injury. Neurotrauma Reports, 5 (1), 640-659. doi: 10.1089/neur.2023.0111 |
|
2024 Journal Article Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancerButeau, James P., Moon, Daniel, Fahey, Michael T., Roberts, Matthew J., Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, De Abreu Lourenco, Richard, Dhillon, Haryana M., Kasivisvanathan, Veeru, Francis, Roslyn J., Stricker, Phillip, Agrawal, Shihka, O'Brien, Jonathan, McVey, Aoife, Sharma, Gaurav, Levy, Sidney, Ayati, Narjess, Nguyen, Andrew, Lee, Su-Faye, Pattison, David A., Sivaratnam, Dinesh, Frydenberg, Mark, Du, Yang, Titus, Jehan, Lee, Sze-Ting, Ischia, Joseph, Jack, Greg ... Emmett, Louise (2024). Clinical trial protocol for PRIMARY2: a multicentre, phase 3, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography in men with negative or equivocal multiparametric magnetic resonance imaging for the diagnosis of clinically significant prostate cancer. European Urology Oncology, 7 (3), 544-552. doi: 10.1016/j.euo.2023.11.008 |
|
2024 Journal Article An automated radiosynthesis of [68Ga]Ga-FAPI-46 for routine clinical useMorandeau, Laurence, Ioppolo, Joseph A., Alvarez de Eulate, Eva, Mohamed, Shifaza, Cullen, Danica, Asad, Ali H., Francis, Roslyn J. and Atkinson, Janette (2024). An automated radiosynthesis of [68Ga]Ga-FAPI-46 for routine clinical use. Journal of Visualized Experiments, 2024 (207) e66708. doi: 10.3791/66708 |
|
2024 Journal Article [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Gedye, Craig, Rutherford, Natalie K., Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P., Voskoboynik, Mark, Redfern, Andrew D., Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Davis, Ian D. (2024). [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. The Lancet Oncology, 25 (5), 563-571. doi: 10.1016/s1470-2045(24)00135-9 |
|
2024 Journal Article Plasma lipoprotein(a) is associated with calcification activity of the thoracic aorta and aortic valve in statin naïve individuals with diabetes mellitusBellinge, Jamie W., Chan, Dick C., Pang, Jing, Francis, Roslyn J., Page, Michael M., Watts, Gerald F. and Schultz, Carl J. (2024). Plasma lipoprotein(a) is associated with calcification activity of the thoracic aorta and aortic valve in statin naïve individuals with diabetes mellitus. European Journal of Clinical Investigation, 54 (5) e14167. doi: 10.1111/eci.14167 |
|
2024 Journal Article Evaluating the impact of FET PET on radiotherapy target volume delineation: Results of the radiation oncology credentialing program from the prospective, multi-centre trial evaluating FET PET in glioblastoma (FIG) study – TROG 18.06Barry, Nathaniel, Koh, Eng-Siew, Ebert, Martin A., Moore, Alisha, Francis, Roslyn J., Rowshanfarzad, Pejman, Mubashar Hassan, Ghulam, Ng, Sweet P., Back, Michael, Chua, Benjamin, Pinkham, Mark B, Pullar, Andrew, Phillips, Claire, Sia, Joseph, Gorayski, Peter, Le, Hien, Gill, Suki, Croker, Jeremy, Bucknell, Nicholas, Bettington, Catherine, Syed, Farhan, Jung, Kylie, Chang, Joe, Bece, Andrej, Clark, Catherine, Wada, Mori, Cook, Olivia, Whitehead, Angela, Rossi, Alana ... Scott, Andrew M. (2024). Evaluating the impact of FET PET on radiotherapy target volume delineation: Results of the radiation oncology credentialing program from the prospective, multi-centre trial evaluating FET PET in glioblastoma (FIG) study – TROG 18.06. Physics and Imaging in Radiation Oncology, 30 100568, 1-8. doi: 10.1016/j.phro.2024.100568 |
|
2024 Journal Article The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy – a prospective cohort studyMay, Isaac J., Nowak, Anna K., Francis, Roslyn J., Ebert, Martin A. and Dhaliwal, Satvinder S. (2024). The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy – a prospective cohort study. Journal of Medical Imaging and Radiation Oncology, 68 (1), 57-66. doi: 10.1111/1754-9485.13592 |
|
2024 Journal Article The impact of fluorine-18-fluoroethyltyrosine positron emission tomography scan timing on radiotherapy planning in newly diagnosed patients with glioblastomaRyan, John, Hardcastle, Nicholas, Francis, Roslyn, Ferjančič, Peter, Ng, Sweet Ping, Koh, Eng-Siew, Geso, Moshi, Kelly, Jennifer and Ebert, Martin A. (2024). The impact of fluorine-18-fluoroethyltyrosine positron emission tomography scan timing on radiotherapy planning in newly diagnosed patients with glioblastoma. Physics and Imaging in Radiation Oncology, 29 100536, 100536. doi: 10.1016/j.phro.2024.100536 |
